journal article·2022-10-05

New Cocrystallization Method: Non-photochemical Laser-Induced Nucleation of a Cocrystal of Caffeine–Gallic Acid in Water

Dania Mellah, Béatrice Nicolaï, Bertrand Fournier, Nada Bošnjaković-Pavlović, Francois-Xavier Legrand, Pascale Gemeiner, Vincent Boemare, Nicolas Guiblin, Ali Assi, Ali Tfayli, Sokona Konate, Pierrick Durand, Anne Spasojević-de Biré

Crystal Growth & Design· Volume 22· Issue 10
Publisher page

Abstract

This paper reports for the first time the crystallization of cocrystals (caffeine–gallic acid) in water using the non-photochemical laser-induced nucleation (NPLIN) technique. The nucleation temporal control of NPLIN and the induction time reduction (70 times shorter than spontaneous nucleation) allow the obtention of cocrystals on demand, with excellent repeatability. Prior to NPLIN experiments, solubility measurements, metastable zone limit determination, and spontaneous nucleation (SN) are carried out. Supersaturated solutions at three different molarities of caffeine (0.0158, 0.0167, and 0.0179 M) are prepared and dissolved at 338 K. Supersaturated solutions are exposed to a 532 nm-wavelength nanosecond pulsed laser at 296 K. Some hours later, crystals can be filtered. The impact of supersaturation on probability of nucleation has been studied, and the result shows a higher supersaturation, which implies a higher probability of nucleation. Crystalline form characterization has employed a combination of Raman scattering, high-performance liquid chromatography, thermogravimetry, differential scanning calorimetry, and powder X-ray diffraction; the sizes of the cocrystals are too small for a single-crystal X-ray diffraction experiment. Two different cocrystal forms are obtained: a new polymorph of hemihydrate CAFGAL.0.5H2O from spontaneous nucleation by precipitation and a new hydrate form CAFGAL.1.5H2O from NPLIN and from spontaneous nucleation of a supersaturated solution without evaporation. These results open a promising way to crystallize cocrystals in the context of the pharmaceutical industry.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Crystallization and Solubility Studies · Crystallography and molecular interactions · Enzyme Structure and Function

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Université Paris-Saclay, CentraleSupélec, CNRS, Laboratoire SPMS, 91190 Gif-sur-Yvette, France

Université Paris-Saclay, CNRS, Institut Galien Paris-Saclay, 92296 Châtenay-Malabry, France

Faculté de Pharmacie, Université Paris-Cité, 75006 Paris, France

Université Paris-Saclay, Lipides: Systèmes Analytiques et Biologiques, EA7357, 92296 Châtenay-Malabry, France

Université Paris-Saclay, CentraleSupélec, ENS Paris-Saclay, CNRS, LMPS-Laboratoire de Mécanique Paris-Saclay, 91190 Gif-sur-Yvette, France

Laboratoire de Cristallographie, Résonance Magnétique et Modélisations (CRM2) UMR 7036 CNRS, Université de Lorraine, Boulevard des Aiguillettes, 54506 Vandoeuvre-Lès-Nancy Cedex, France

References (96)

Show source-provided references
1. 10.1103/physrevlett.77.347510.1103/physrevlett.77.3475 ↗
2. 10.1016/s0022-0248(01)02266-710.1016/s0022-0248(01)02266-7 ↗
3. 10.1143/jjap.42.l79810.1143/jjap.42.l798 ↗
4. 10.1021/cg049709y10.1021/cg049709y ↗
5. 10.1103/PhysRevLett.99.04570110.1103/PhysRevLett.99.045701 ↗
6. 10.1246/cl.2007.148010.1246/cl.2007.1480 ↗
7. 10.1007/s00339-008-4790-x10.1007/s00339-008-4790-x ↗
8. 10.1021/cg100830x10.1021/cg100830x ↗
9. 10.1021/jp907233410.1021/jp9072334 ↗
10. 10.1021/cg200001410.1021/cg2000014 ↗
11. 10.1021/cg301024t10.1021/cg301024t ↗
12. 10.16943/ptinsa/2015/v81i2/4810410.16943/ptinsa/2015/v81i2/48104 ↗
13. 10.1038/s41557-018-0009-810.1038/s41557-018-0009-8 ↗
14. 10.1039/c9sm01297d10.1039/c9sm01297d ↗
15. 10.1107/s160057671401098x10.1107/s160057671401098x ↗
16. 10.1063/1.507932810.1063/1.5079328 ↗
17. 10.1016/j.jphotochemrev.2022.10053010.1016/j.jphotochemrev.2022.100530 ↗
18. 10.1002/jccs.20210026910.1002/jccs.202100269 ↗
19. 10.1039/c7cp06990a10.1039/c7cp06990a ↗
20. 10.1021/cg800741510.1021/cg8007415 ↗
21. 10.1021/acsomega.0c0490210.1021/acsomega.0c04902 ↗
22. 10.1021/jacs.1c1115410.1021/jacs.1c11154 ↗
23. 10.1021/cg050041c10.1021/cg050041c ↗
24. 10.1107/S160057672100540910.1107/S1600576721005409 ↗
25. 10.1111/jphp.1237510.1111/jphp.12375 ↗
26. 10.2174/09298670978754929910.2174/092986709787549299 ↗
27. 10.1039/d1ce01327k10.1039/d1ce01327k ↗
28. 10.1016/j.apsb.2021.03.03010.1016/j.apsb.2021.03.030 ↗
29. 10.1021/cg800028v10.1021/cg800028v ↗
30. 10.1021/acs.cgd.9b0012310.1021/acs.cgd.9b00123 ↗
31. 10.1021/cg500163c10.1021/cg500163c ↗
32. 10.7567/apex.8.04550110.7567/apex.8.045501 ↗
33. 10.1021/acs.cgd.5b0152610.1021/acs.cgd.5b01526 ↗
34. 10.1021/acs.cgd.0c0147610.1021/acs.cgd.0c01476 ↗
35. 10.7567/1882-0786/aaf41910.7567/1882-0786/aaf419 ↗
36. 10.1021/cg049654010.1021/cg0496540 ↗
37. 10.1021/cg050168210.1021/cg0501682 ↗
38. 10.1021/mp070005410.1021/mp0700054 ↗
39. 10.1021/cg700929e10.1021/cg700929e ↗
40. 10.1021/cg801178m10.1021/cg801178m ↗
41. 10.1021/cg901345u10.1021/cg901345u ↗
42. 10.1111/jfpe.1306610.1111/jfpe.13066 ↗
43. 10.1016/j.fluid.2017.09.02110.1016/j.fluid.2017.09.021 ↗
44. 10.1107/s205698901800452810.1107/s2056989018004528 ↗
45. 10.1007/s10870-010-9766-y10.1007/s10870-010-9766-y ↗
46. 10.1039/c0ce00214c10.1039/c0ce00214c ↗
47. 10.1039/c2ce25080b10.1039/c2ce25080b ↗
48. 10.1039/c3sc51419f10.1039/c3sc51419f ↗
49. 10.1016/j.molstruc.2012.10.03310.1016/j.molstruc.2012.10.033 ↗
50. 10.1016/j.molstruc.2012.12.02210.1016/j.molstruc.2012.12.022 ↗
51. 10.1134/s002247661305024710.1134/s0022476613050247 ↗
52. 10.1021/cg400928v10.1021/cg400928v ↗
53. 10.1016/j.molstruc.2013.07.01810.1016/j.molstruc.2013.07.018 ↗
54. 10.1039/c4ce01495b10.1039/c4ce01495b ↗
55. 10.1039/c4ce00472h10.1039/c4ce00472h ↗
56. 10.1002/slct.20190111110.1002/slct.201901111 ↗
57. 10.1021/acs.molpharmaceut.9b0037710.1021/acs.molpharmaceut.9b00377 ↗
58. 10.1039/d0ce01064b10.1039/d0ce01064b ↗
59. 10.1021/acs.cgd.0c0030110.1021/acs.cgd.0c00301 ↗
60. 10.1021/acs.cgd.0c0124210.1021/acs.cgd.0c01242 ↗
61. 10.1016/j.supflu.2010.01.01010.1016/j.supflu.2010.01.010 ↗
62. 10.1021/mp200209j10.1021/mp200209j ↗
63. 10.1021/cg401179s10.1021/cg401179s ↗
64. 10.1039/c4ce00103f10.1039/c4ce00103f ↗
65. 10.1007/s10973-013-3031-510.1007/s10973-013-3031-5 ↗
66. 10.1016/j.molstruc.2014.07.03610.1016/j.molstruc.2014.07.036 ↗
67. 10.1016/j.colsurfa.2014.02.03410.1016/j.colsurfa.2014.02.034 ↗
68. 10.1021/acs.cgd.6b0059110.1021/acs.cgd.6b00591 ↗
69. 10.1016/j.ejps.2016.12.01610.1016/j.ejps.2016.12.016 ↗
70. 10.1021/acs.cgd.6b0186310.1021/acs.cgd.6b01863 ↗
71. 10.1039/c7ce00284j10.1039/c7ce00284j ↗
72. 10.1021/acs.cgd.7b0074810.1021/acs.cgd.7b00748 ↗
73. 10.1080/03639045.2018.143568710.1080/03639045.2018.1435687 ↗
74. 10.1039/c8ce00084k10.1039/c8ce00084k ↗
75. 10.1208/s12249-018-1101-510.1208/s12249-018-1101-5 ↗
76. 10.1039/c8nj02647e10.1039/c8nj02647e ↗
77. 10.1016/j.jddst.2019.02.00410.1016/j.jddst.2019.02.004 ↗
78. 10.1208/s12249-019-1324-010.1208/s12249-019-1324-0 ↗
79. 10.1039/c9nj01848d10.1039/c9nj01848d ↗
80. 10.1021/acs.cgd.9b0093110.1021/acs.cgd.9b00931 ↗
81. 10.3390/cryst1012108810.3390/cryst10121088 ↗
82. 10.1089/adt.2020.105210.1089/adt.2020.1052 ↗
83. 10.1021/acs.cgd.1c0000510.1021/acs.cgd.1c00005 ↗
84. 10.3390/pharmaceutics1312214010.3390/pharmaceutics13122140 ↗
85. 10.3390/pharmaceutics1402033410.3390/pharmaceutics14020334 ↗
86. Shalmashi A. · Lat. Am. Appl. Res. · 2010 · 40 · 283
87. 10.1016/j.saa.2018.05.00210.1016/j.saa.2018.05.002 ↗
88. 10.1021/cg301506x10.1021/cg301506x ↗
89. 10.1021/acs.jpcb.1c0262010.1021/acs.jpcb.1c02620 ↗
90. 10.1107/S002188988001193410.1107/S0021889880011934 ↗
91. 10.1107/s002188980401487610.1107/s0021889804014876 ↗
92. Rodriguez-Carvajal, J.; Roisnel, T. FullProf.98 and WinPLOTR: New Windows 95/NT Applications for Diffraction Commission for Powder Diffraction, 1998.
93. 10.1016/j.saa.2004.10.02210.1016/j.saa.2004.10.022 ↗
94. 10.25518/1780-4507.1627010.25518/1780-4507.16270 ↗
95. 10.1016/s0166-1280(02)00547-x10.1016/s0166-1280(02)00547-x ↗
96. 10.1021/cg801039j10.1021/cg801039j ↗